Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0I1FQ
|
||||
Former ID |
DAP001510
|
||||
Drug Name |
Raltegravir
|
||||
Synonyms |
RGV; MK 0518; Isentress(TM); K-0518; MK-0518; Raltegravir (INN); N-(2-(4-(4-fluorobenzylcarbamoyl); N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo-4-pyrimidinecarboxamide; RAL
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] | Approved | [529282] | ||
Structure |
Download2D MOL |
||||
Formula |
C20H21FN6O5
|
||||
CAS Number |
CAS 871038-72-1
|
||||
PubChem Compound ID | |||||
SuperDrug ATC ID |
J05AX08
|
||||
Drug Resistance Mutation (DRM) | |||||
DRM | DRM Info | ||||
Target and Pathway | |||||
Target(s) | HIV integrase | Target Info | Modulator | [529282] | |
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.